Contribute Try STAT+ Today

Cancer, with all its wiles, has figured out how to withstand science’s best efforts by tapping a secret genetic arsenal. One company aims to kill drug-resistant tumors by cutting off their resupply.

Scores of treatments work by targeting cancer-causing genes like EGFR and HER2. But the trickiest tumors have devised a way to replace the malignant genes by reaching into tiny circles of DNA floating inside cancer cells, allowing tumors to grow despite a pharmaceutical assault. At Boundless Bio, which just raised $46 million in venture funding, the idea is to knock out the backup DNA before cancer can reload.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.